Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PL-18 Vaginal Suppositories in Healthy Women
NCT05340790Phase 1Recruiting
- Sponsor
- Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.
- Start
- Aug 2022
- Primary completion
- Dec 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in bacterial vaginosis (BV), vulvovaginal candidiasis (VVC) and mixed vaginitis comparing PL-18 with Placebo (2 arms). Primary endpoints: Treatment Emergent Adverse Events at 38 days, Incidence of Vital Sign Abnormalities at 17 days and 3 more. Started Aug 2022; status: recruiting.
02
Drugs
PL-18
03
Conditions
bacterial vaginosis (BV)vulvovaginal candidiasis (VVC)mixed vaginitis
Beyond the preview
Go deeper on NCT05340790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05340790.